Kimberly A. Kraynyak, Ph.D. - Publications

Affiliations: 
2009 University of Pennsylvania, Philadelphia, PA, United States 
Area:
DNA vaccine, HIV

22/38 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Shore ND, Morrow MP, McMullan T, Kraynyak KA, Sylvester A, Bhatt K, Cheung J, Boyer JD, Liu L, Sacchetta B, Rosencranz S, Heath EI, Nordquist L, Cheng HH, Tagawa ST, et al. CD8 T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 32208168 DOI: 10.1016/j.ymthe.2020.02.018  0.4
2020 Aggarwal C, Cohen RB, Morrow MP, Kraynyak KA, Sylvester AJ, Cheung J, Dickerson K, Schulten V, Knoblock D, Gillespie E, Bauml JM, Yan J, Diehl M, Boyer J, Dallas M, et al. Immune Therapy Targeting E6/E7 Oncogenes of Human Paillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis. Vaccines. 8. PMID 32013270 DOI: 10.3390/vaccines8010056  0.4
2019 Tebas P, Kraynyak KA, Patel A, Maslow JN, Morrow MP, Sylvester AJ, Knoblock D, Gillespie E, Amante D, Racine T, McMullan T, Jeong M, Roberts CC, Park YK, Boyer J, et al. Intradermal SynCon® Ebola GP DNA Vaccine is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers. The Journal of Infectious Diseases. PMID 30891607 DOI: 10.1093/infdis/jiz132  0.4
2018 Patel A, Reuschel EL, Kraynyak KA, Racine T, Park DH, Scott VL, Audet J, Amante D, Wise MC, Keaton AA, Wong G, Villarreal DO, Walters J, Muthumani K, Shedlock DJ, et al. Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines. The Journal of Infectious Diseases. PMID 30304515 DOI: 10.1093/infdis/jiy537  0.4
2018 Schultheis K, Smith TRF, Kiosses WB, Kraynyak KA, Wong A, Oh J, Broderick KE. Delineating the cell death mechanisms associated with skin electroporation. Human Gene Therapy Methods. PMID 29953259 DOI: 10.1089/hgtb.2017.105  0.36
2017 Morrow MP, Kraynyak K, Sylvester AJ, Dallas M, Knoblock D, Boyer J, Yan J, Vang R, Khan AS, Humeau L, Sardesai NY, Kim JJ, Plotkin S, Weiner D, Trimble CL, et al. Clinical and Immunological Biomarkers for Histologic Regression of High Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29084917 DOI: 10.1158/1078-0432.CCR-17-2335  0.4
2017 Muthumani K, Marnin L, Kudchodkar SB, Perales-Puchalt A, Choi H, Agarwal S, Scott VL, Reuschel EL, Zaidi FI, Duperret EK, Wise MC, Kraynyak KA, Ugen KE, Sardesai NY, Joseph Kim J, et al. Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody. Cancer Immunology, Immunotherapy : Cii. PMID 28819703 DOI: 10.1007/s00262-017-2042-7  0.4
2017 Smith TRF, Schultheis K, Morrow MP, Kraynyak KA, McCoy JR, Yim KC, Muthumani K, Humeau L, Weiner DB, Sardesai NY, Broderick KE. Development of an intradermal DNA vaccine delivery strategy to achieve single-dose immunity against respiratory syncytial virus. Vaccine. PMID 28413132 DOI: 10.1016/j.vaccine.2017.04.008  0.4
2017 Walters JN, Ferraro B, Duperret EK, Kraynyak KA, Chu J, Saint-Fleur A, Yan J, Levitsky H, Khan AS, Sardesai NY, Weiner DB. A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 28237837 DOI: 10.1016/j.ymthe.2017.01.022  0.4
2016 Muthumani K, Griffin BD, Agarwal S, Kudchodkar SB, Reuschel EL, Choi H, Kraynyak KA, Duperret EK, Keaton AA, Chung C, Kim YK, Booth SA, Racine T, Yan J, Morrow MP, et al. In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine. Npj Vaccines. 1: 16021. PMID 29263859 DOI: 10.1038/npjvaccines.2016.21  0.4
2016 Morrow MP, Kraynyak KA, Sylvester AJ, Shen X, Amante D, Sakata L, Parker L, Yan J, Boyer J, Roh C, Humeau L, Khan AS, Broderick K, Marcozzi-Pierce K, Giffear M, et al. Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100. Molecular Therapy Oncolytics. 3: 16025. PMID 28054033 DOI: 10.1038/mto.2016.25  0.4
2015 Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, Brown AS, Marcozzi-Pierce K, Shah D, Slager AM, Sylvester AJ, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet (London, England). PMID 26386540 DOI: 10.1016/S0140-6736(15)00239-1  0.4
2015 Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO, Wise M, Patel A, Izmirly A, Aljuaid A, Seliga AM, Soule G, Morrow M, Kraynyak KA, Khan AS, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Science Translational Medicine. 7: 301ra132. PMID 26290414 DOI: 10.1126/scitranslmed.aac7462  0.4
2015 Morrow MP, Tebas P, Yan J, Ramirez L, Slager A, Kraynyak K, Diehl M, Shah D, Khan A, Lee J, Boyer J, Kim JJ, Sardesai NY, Weiner DB, Bagarazzi ML. Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 591-601. PMID 25531694 DOI: 10.1038/mt.2014.245  0.4
2014 Yan J, Tingey C, Lyde R, Gorham TC, Choo DK, Muthumani A, Myles D, Weiner LP, Kraynyak KA, Reuschel EL, Finkel TH, Kim JJ, Sardesai NY, Ugen KE, Muthumani K, et al. Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model. Cancer Gene Therapy. 21: 507-17. PMID 25394503 DOI: 10.1038/cgt.2014.56  0.4
2012 Kathuria N, Kraynyak KA, Carnathan D, Betts M, Weiner DB, Kutzler MA. Generation of antigen-specific immunity following systemic immunization with DNA vaccine encoding CCL25 chemokine immunoadjuvant. Human Vaccines & Immunotherapeutics. 8: 1607-19. PMID 23151454 DOI: 10.4161/hv.22574  0.4
2012 Morello CS, Kraynyak KA, Levinson MS, Chen Z, Lee KF, Spector DH. Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge. Vaccine. 30: 6541-50. PMID 22947141 DOI: 10.1016/j.vaccine.2012.08.049  0.4
2011 Morello CS, Levinson MS, Kraynyak KA, Spector DH. Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease. Journal of Virology. 85: 3461-72. PMID 21270160 DOI: 10.1128/JVI.02521-10  0.4
2010 Kraynyak KA, Kutzler MA, Cisper NJ, Khan AS, Draghia-Akli R, Sardesal NY, Lewis MG, Yan J, Weiner DB. Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques. Vaccine. 28: 1942-51. PMID 20188250 DOI: 10.1016/j.vaccine.2009.10.095  0.4
2010 Kutzler MA, Kraynyak KA, Nagle SJ, Parkinson RM, Zharikova D, Chattergoon M, Maguire H, Muthumani K, Ugen K, Weiner DB. Plasmids encoding the mucosal chemokines CCL27 and CCL28 are effective adjuvants in eliciting antigen-specific immunity in vivo. Gene Therapy. 17: 72-82. PMID 19847203 DOI: 10.1038/gt.2009.112  0.4
2009 Kraynyak KA, Kutzler MA, Cisper NJ, Laddy DJ, Morrow MP, Waldmann TA, Weiner DB. Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo. Human Gene Therapy. 20: 1143-56. PMID 19530914 DOI: 10.1089/hum.2009.025  0.4
2009 Kraynyak KA, Kutzler MA, Pahar B, Sylvester A, Yan J, Carnathan D, Khan AS, Sardesai N, Moldoveanu Z, Mestecky J, Betts MR, Marx P, Weiner DB. P19-46. Co-delivery of mucosal chemokine plasmids in a systemically delivered DNA vaccine elicits systemic and mucosal immune responses in mice and macaques Retrovirology. 6: P366. DOI: 10.1186/1742-4690-6-S3-P366  0.4
Low-probability matches
2015 Kraynyak KA, Bodles-Brakhop A, Bagarazzi M. Tapping the Potential of DNA Delivery with Electroporation for Cancer Immunotherapy. Current Topics in Microbiology and Immunology. PMID 25682101 DOI: 10.1007/82_2015_431  0.16
2020 Hasan Y, Furtado L, Tergas A, Lee N, Brooks R, McCall A, Golden D, Jolly S, Fleming G, Morrow M, Kraynyak K, Sylvester A, Arif F, Levin M, Schwartz D, et al. A Phase I trial assessing the safety and tolerability of a therapeutic DNA vaccination against HPV16 and HPV18 E6/E7 oncogenes after chemoradiation for cervical cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 32151670 DOI: 10.1016/j.ijrobp.2020.02.031  0.12
2018 Shore N, Heath EI, Nordquist LT, Cheng H, Bhatt K, Morrow M, McMullan T, Kraynyak K, Lee J, Sacchetta B, Liu L, Rosencranz S, Tagawa ST, Appleman LJ, Tutrone R, et al. Synthetic DNA immunotherapy in biochemically relapsed prostate cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii290. PMID 32136666 DOI: 10.1093/annonc/mdy284.039  0.12
2018 Aggarwal C, Cohen RB, Morrow MP, Kraynak KA, Sylvester AJ, Knoblock DM, Bauml J, Weinstein GS, Lin A, Boyer J, Sakata L, Tan S, Anton A, Dickerson K, Mangrolia D, et al. Immunotherapy targeting HPV 16/18 generates potent immune responses in HPV-Associated Head and Neck Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30242022 DOI: 10.1158/1078-0432.CCR-18-1763  0.04
2020 Skolnik J, Reardon D, Brem S, Desai A, Bagley S, Kurz S, Fuente Mdl, Nagpal S, Welch M, Sacchetta B, Bartra S, Bredlau A, Lowy I, Kraynyak K, Morrow M, et al. P858 An open-label, multi-center trial of INO-5401 and INO-9012 delivered by electroporation (EP) in combination with cemiplimab in subjects with newly-diagnosed glioblastoma (GBM) Journal For Immunotherapy of Cancer. 8: A8.1-A8. DOI: 10.1136/LBA2019.12  0.01
2019 Bernstein DI, Morello CS, Cardin RD, Bravo FJ, Kraynyak KA, Spector DH. A vaccine containing highly purified virus particles in adjuvant provides high level protection against genital infection and disease in guinea pigs challenged intravaginally with homologous and heterologous strains of herpes simplex virus type 2. Vaccine. PMID 31611098 DOI: 10.1016/j.vaccine.2019.09.090  0.01
2018 Shore ND, Heath EI, Nordquist LT, Cheng HH, Bhatt K, Morrow M, McMullan T, Kraynyak K, Lee J, Sacchetta B, Liu L, Rosencranz S, Tagawa ST, Parikh RA, Tutrone RF, et al. Evaluation of an immunotherapeutic DNA-vaccine in biochemically relapsed prostate cancer. Journal of Clinical Oncology. 36: 5078-5078. DOI: 10.1200/JCO.2018.36.15_suppl.5078  0.01
2017 Shore ND, Heath EI, Nordquist LT, Cheng HH, Bhatt K, Carroll N, Kraynyak K, Lee J, Van Tornout J, Sacchetta B, Tagawa ST, Parikh RA, Tutrone RF, Garcia JA, Whang YE, et al. A clinical trial for the safety and immunogenicity of a DNA-based immunotherapy in men with biochemically (PSA) relapsed prostate cancer. Journal of Clinical Oncology. 35: 80-80. DOI: 10.1200/JCO.2017.35.6_suppl.80  0.01
2017 Aggarwal C, Cohen RB, Morrow MP, Kraynyak K, Bauml J, Weinstein GS, Boyer J, Yan J, Mangrolia D, Oyola S, Duff S, Weiner DB, Csiki I, Bagarazzi ML. Immunogenicity results using human papillomavirus (HPV) specific DNA vaccine, INO-3112 (HPV16/HPV18 plasmids + IL-12) in HPV+ head and neck squamous cell carcinoma (HNSCCa). Journal of Clinical Oncology. 35: 6073-6073. DOI: 10.1200/jco.2017.35.15_suppl.6073  0.01
2017 Csiki I, Shore N, Bhatt K, Morrow M, Kraynyak K, Liu L, McMullan T, Lee J, Sachetta B, Rosencranz S, Heath E, Bagarazzi M. INO-5150 (PSA and PSMA) +/- INO-9012 (IL-12) immunotherapy in biochemically relapsed prostate cancer Annals of Oncology. 28: xi5. DOI: 10.1093/annonc/mdx710.007  0.01
2017 Shore N, Heath E, Nordquist L, Cheng H, Bhatt K, Morrow M, McMullan T, Kraynyak K, Lee J, Sacchetta B, Liu L, Rosencranz S, Tagawa S, Parikh R, Tutrone R, et al. Safety and immunogenicity of a DNA-vaccine immunotherapy in men with biochemically (PSA) relapsed prostate cancer Annals of Oncology. 28: v272. DOI: 10.1093/annonc/mdx370.007  0.01
2016 Morrow M, Trimble C, Shen X, Dallas M, Weiner D, Boyer J, Yan J, Kraynyak K, Sylester A, Giffear M, Marcozzi-Pierce K, Shah D, Broderick K, Khan A, Lee J, et al. 505. VGX-3100 Drives Regression of HPV16/18 CIN2/3 and Robust Cellular Immune Responses in Blood and Cervical Tissue in a Blinded, Randomized, Placebo-Controlled Phase 2B Study Molecular Therapy. 24: S201. DOI: 10.1016/S1525-0016(16)33314-7  0.01
2016 Patel A, Reuschel EL, Kraynyak KA, Racine T, Park DH, Keaton AA, Karuppiah M, Shedlock D, Yan J, Khan A, Tierney K, Sardesai N, Kobinger GP, Weiner DB. 479. An Optimized DNA Vaccine Formulation Protects Against Lethal Ebola Makona Virus Challenge in Non-Human Primates and Elicits Robust Immune Responses Molecular Therapy. 24: S189-S190. DOI: 10.1016/S1525-0016(16)33288-9  0.01
2015 Patel A, Reuschel EL, Scott VL, Kraynyak KA, Wong G, Villarreal DO, Karuppiah M, Shedlock D, Yan J, Broderick KE, Khan A, Tierney K, Kobinger GP, Sardesai N, Weiner DB. 450. A Single Immunization With Optimized DNA Vaccines Protects Against Lethal Ebola Virus Challenge in Mice and Induces Seroconversion in Non-Human Primates Following a DNA Prime–DNA Boost Approach Molecular Therapy. 23: S178-S179. DOI: 10.1016/S1525-0016(16)34059-X  0.01
2015 Yan J, Chu JS, Obeng-Adjei N, Morrow MP, Kraynyak K, Slager AM, Yang M, Khan AS, Broderick KE, Sardesai NY, Weiner DB. 417. Induction of Potent Cytotoxic and Antitumor Activity By a Highly Optimized hTERT DNA Vaccine Molecular Therapy. 23: S165. DOI: 10.1016/S1525-0016(16)34026-6  0.01
2014 Morrow MP, Kraynyak K, Shen X, Knott C, Yan J, Broderick K, Khan A, Giffear M, Lee J, Boyer J, Weiner D, Sardesai N, Bagarazzi M. Boosting of cellular and humoral immune responses to HPV16/18 antigens by VGX-3100: A follow-on phase I trial. Journal of Clinical Oncology. 32: 3101-3101. DOI: 10.1200/jco.2014.32.15_suppl.3101  0.01
Hide low-probability matches.